Author details

Full Name

Sudeh Izadmehr

Affiliation

ORCID

Career Start Year

2012

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36525217	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics).		2023
36862334	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics).		2023
36099881	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.	Cancer Cell	2022
34646777	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.	Frontiers in Oncology	2021
33837006	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.	Clin Cancer Res	2021
33027304	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.	PLoS One	2020
32315618	Selective PP2A Enhancement through Biased Heterotrimer Stabilization.	Cell	2020
32356252	COVID-19: Therapeutics and Their Toxicities.	J Med Toxicol	2020
31822503	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.	J Biol Chem	2020
30830869	Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.	JCI Insight	2019
30646921	Sequential trafficking of Env and Gag to HIV-1 T cell virological synapses revealed by live imaging.	Retrovirology	2019
31070948	MIFEPRISTONE TREATMENT FOR MILD AUTONOMOUS CORTISOL SECRETION DUE TO ADRENAL ADENOMAS: A PILOT STUDY.	Endocrine Practice	2019
31259909	Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts.	Journal of Visualized Experiments	2019
30842989	Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase.	Journal of the Endocrine Society	2019
29376892	Factor XII and uPAR upregulate neutrophil functions to influence wound healing.	Journal of Clinical Investigation	2018
30021885	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.	Sci Transl Med	2018
29358171	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.	Cancer Res	2018
28538730	Blocking FSH induces thermogenic adipose tissue and reduces body fat.	Nature	2017
28504649	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.	J Clin Invest	2017
28674022	FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.	Proceedings of the National Academy of Sciences of the United States of America	2017
27783536	Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases.	Endocrinology	2016
27318820	Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.	International Urology and Nephrology	2016
27562410	Erratum to: Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.	International Urology and Nephrology	2016
24608435	Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.	Oncogene	2015
26372073	Reengineered tricyclic anti-cancer agents.	Bioorg Med Chem	2015
28290285	Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].	Bioorg Med Chem	2015
24398473	Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.	Cancer Res	2014
25453081	Bisphosphonates inactivate human EGFRs to exert antitumor actions.	Proc Natl Acad Sci U S A	2014
25453078	Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.	Proc Natl Acad Sci U S A	2014
23345610	KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.	Sci Transl Med	2013
23152056	Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens.	Cell Death and Disease	2012
22653055	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.	J Clin Invest	2012